The content on this website has been developed solely by Celgene.

NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY
(NCCN GUIDELINES®) RECOMMENDATIONS10*

Initial Systemic Therapy
Advanced or Metastatic Squamous Cell NSCLC
Albumin-bound paclitaxel (ABRAXANE)
+ carboplatin + pembrolizumab

NCCN

Category 1 for PD-L1 ≥50%a
Category 1 Preferred for PD-L1 1%-49%a
Albumin-bound paclitaxel (ABRAXANE) + carboplatin + pembrolizumab is a treatment option included in the NCCN Guidelines for Non-Small Cell Lung Cancer with a Category 1 (preferred) recommendation for the first-line treatment of patients with metastatic NSCLC squamous cell carcinoma and PD-L1 1%-49% (PS 0-1)b,c

  • *For additional considerations and treatment options, see NCCN.org.
  • a Category 1: Based on high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
  • b If progression on PD-1/PD-L1 inhibitor, switching to another PD-1/PD-L1 inhibitor is not routinely recommended.
  • c PD-L1 ≥1% and EGFR, ALK negative or unknown, treatment option for patients with no contraindications to the addition of pembrolizumab or atezolizumab. Contraindications for treatment with PD-1/PD-L1 inhibitors may include active or previously documented autoimmune disease and/or current use of immunosuppressive agents or presence of an oncogene, which would predict lack of benefit.
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRAXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL